Fosamprenavir
- Generic Name
- Fosamprenavir
- Brand Names
- Lexiva, Telzir
- Drug Type
- Small Molecule
- Chemical Formula
- C25H36N3O9PS
- CAS Number
- 226700-79-4
- Unique Ingredient Identifier
- WOU1621EEG
- Background
Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.
- Indication
Indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. The use of fosamprenavir is pending revision due to a potential association between the drug and myocardial infarction and dyslipidemia in HIV infected adults.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
- First Posted Date
- 2002-07-10
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 69
- Registration Number
- NCT00040664
- Locations
- ๐ช๐ธ
GSK Investigational Site, Valencia, Spain
Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People
- Conditions
- HIV Infections
- First Posted Date
- 2001-12-28
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 56
- Registration Number
- NCT00028366
- Locations
- ๐บ๐ธ
USC CRS, Los Angeles, California, United States
๐บ๐ธThe Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
๐บ๐ธCase CRS, Cleveland, Ohio, United States
Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV
- Conditions
- HIV Infections
- First Posted Date
- 2001-12-05
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 53
- Registration Number
- NCT00027339
- Locations
- ๐บ๐ธ
USC CRS, Los Angeles, California, United States
๐บ๐ธUC Davis Medical Center, Sacramento, California, United States
๐บ๐ธBeth Israel Med. Ctr., ACTU, New York, New York, United States
Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure
- Conditions
- HIV Infections
- First Posted Date
- 2001-10-16
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 330
- Registration Number
- NCT00025727
- Locations
- ๐บ๐ธ
Bach and Godofsky, Bradenton, Florida, United States
๐บ๐ธTherafirst Med Ctr, Fort Lauderdale, Florida, United States
๐บ๐ธRush Med College / Dept of Infectious Diseases, Chicago, Illinois, United States
Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 624
- Registration Number
- NCT00009061
- Locations
- ๐บ๐ธ
North Jersey Community Research Initiative, Newark, New Jersey, United States
๐บ๐ธNicholas Bellos, Dallas, Texas, United States
๐บ๐ธTherafirst Med Ctr, Fort Lauderdale, Florida, United States
Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 210
- Registration Number
- NCT00008554
- Locations
- ๐บ๐ธ
Ocean View Internal Medicine, Long Beach, California, United States
๐บ๐ธSaint Michael's Med Ctr, Newark, New Jersey, United States
๐บ๐ธHillsborough County Health Dept, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.